The challenge
In a large university hospital, the most clinically sensitive departments face two distinct airborne risks. Immunocompromised patients in haematology wards, including bone-marrow and organ transplant recipients, are vulnerable to airborne pathogens at concentrations that healthy patients would clear without difficulty. A single airborne pathogen in these rooms is a clinical event, not a near-miss.
IVF laboratories carry a different risk: chemical pollution. Volatile organic compounds, formaldehyde and nitrogen oxides present in hospital air can compromise embryo development and IVF outcomes. Standard ventilation controls dilution; it does not destroy the pollutant load at source.
What we did
The technology was introduced to the hospital by its Nosocomial Infection Control Unit, which ran a formal validation programme in 2020. The Unit tested the mechanism, confirmed the performance, and established the evidence base before recommending any deployment.
Based on those findings, air purification units were installed in the specific high-risk departments where the validation supported their use. Each environment placed different demands on the technology: continuous pathogen control for haematology rooms, chemical destruction for the IVF laboratory, and infection control for maxilofacial surgery.
The result
Formally validated, then deployed where patients are most at risk.
The IVF laboratory deployment addressed chemical pollution, including formaldehyde, VOCs and nitrogen oxides, without producing ozone or harmful byproducts. The haematology deployment provides continuous air purification and surface self-disinfection for transplant patients at the highest infection risk. A robotic pharmacy installation was forecast as the next step at the time of the hospital's review.
The 2020 validation was led by Lille University Hospital's own Nosocomial Infection Control Unit, one of France's largest university hospital centres. The evidence base was built from within the hospital's clinical governance structure, not from a manufacturer claim, and deployment followed from those findings. This is a hospital-validated adoption reference; for independent laboratory evidence of the underlying technology, additional test data is held on file.
Why it matters
For healthcare estates and infection control leads, this shows a path beyond standard ventilation and filtration: air purification formally validated by a hospital's own infection control unit and deployed to the most clinically sensitive environments it operates. The same approach applies wherever a duty of care over patient safety meets environments where standard controls carry a residual risk that the clinical team is not prepared to accept.
Tell us your challenge
Tell us the cost, the risk or the obligation you are facing. A senior member of our team will respond, in confidence, with how we would help.